You are here: Industry Insights > Prostate Cancer

News List

FDA grants Clovis’ Rubraca fast track designation for prostate cancer pharmaceutical-technology
January 17, 2020
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) adult patients.
AI System Can Detect, Grade Cancer in Prostate Needle Biopsy drugs
January 16, 2020
An artificial intelligence (AI) system can be used to detect and grade prostate cancer in prostate needle biopsy samples, according to a study published online January in The Lancet Oncology.
Nuclear radiologists 'outsmart' prostate cancer with an apparently ineffective drug worldpharmanews
January 14, 2020
When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewhat remote, rather idealistic genius sitting alone in their room or laboratory and somehow discovering the most amazing things without every having contact wit
Risk-Based Approach Could Help Target Prostate Cancer Screening drugs
December 30, 2019
Risk-tailored screening could potentially reduce overdiagnosis and improve the cost-effectiveness of a prostate cancer screening program, according to a study published online December in PLOS Medicine.
Organ Transplant Does Not Worsen Prostate Cancer Outcome drugs
December 26, 2019
Among older men with prostate cancer, an organ transplant is associated with higher overall mortality, but not prostate cancer-specific mortality (PCSM)
Farrer Park Hospital Implements Non-Invasive Treatment for Prostate Cancer Patients in Singapore En-CPhI.CN
December 10, 2019
Farrer Park Hospital is pleased to announce that it is the first in South East Asia to have implemented the Focal One® High-Intensity Frequency Ultrasound (HIFU) Robotic Technology ...
Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer worldpharmanews
December 10, 2019
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer ...
FDA Grants Astellas/Pfizer’s XTANDI® Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer americanpharmaceuticalreview
August 23, 2019
Astellas Pharma Inc. and Pfizer Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to ...
New late stage prostate cancer technology available in UK pharmatimes
June 05, 2019
GenesisCare has launched a new radiotherapy technology in the UK to treat late stage prostate cancer patients, for whom there are limited treatment options available.
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer fiercepharma
February 24, 2019
When it comes to using Xtandi in hormone-sensitive prostate cancer, Pfizer and Astellas are “really excited,” executives have said. And new data shows the partners have reason to be.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page